EE147 The Cost-Effectiveness of Olaparib Compared to Niraparib in the Treatment of Recurrent Ovarian Cancer Caused By BRCA1 and BRCA2 Gene Mutation from a US Healthcare Payer Perspective.
Abstract
Authors
K Alkhuzam D Guan R Aroza S Abuloha H Shao